Download
1 / 35
0 likes | 5 Vues
Erythropoietin Stimulating Agent Market size is estimated to reach $7.6 billion by 2030, growing at a CAGR of 3.5% over the forecast period 2023-2030. Erythropoietin is a hormone produced by the human kidney that speeds up the creation of red blood cells in response to decreasing oxygen levels in the tissues.
E N D
Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC ERYTHROPOIETIN STIMULATING AGENT MARKET Page - 1 | Web - www.industryarc.com Mail – sales@industryarc.com
Choosing the Right Consulting Partner is Choosing the Choosing the Right Consulting Partner is Choosing the Growth Path OUR EXPERTISE - END TO END CONSULTING Copyright ©2024 IndustryARC IT & Consulting Copyright ©2024 IndustryARC Energy and Power Life sciences and Healthcare Consumer & Retail Electronics Chemicals and Materials Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
TABLE OF CONTENTS Topics Slide No Chapter 01: Erythropoietin Stimulating Agent Market Overview Chapter 01: Erythropoietin Stimulating Agent Market Overview - 004 Chapter 02: Erythropoietin Stimulating Agent Market Executive Summary Chapter 02: Erythropoietin Stimulating Agent Market Executive Summary - 017 Chapter 03: Erythropoietin Stimulating Agent Market Comparative Analysis Chapter 03: Erythropoietin Stimulating Agent Market Comparative Analysis - 021 Chapter 04: Erythropoietin Stimulating Agent Market Forces Chapter 04: Erythropoietin Stimulating Agent Market Forces - 030 Chapter 05: Erythropoietin Stimulating Agent Market Strategic Analysis Chapter 05: Erythropoietin Stimulating Agent Market Strategic Analysis - 039 Chapter 06: Erythropoietin Stimulating Agent Market - By Product Type - 046 Chapter 07: Erythropoietin Stimulating Agent Market - By Disease Cured - 052 Chapter 08: Erythropoietin Stimulating Agent Market - By Application Chapter 08: Erythropoietin Stimulating Agent Market - By Application - 067 Chapter 09: Erythropoietin Stimulating Agent Market - By Geography Chapter 09: Erythropoietin Stimulating Agent Market - By Geography - 071 Chapter 10: Erythropoietin Stimulating Agent Market Entropy - 106 Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Chapter 11: Erythropoietin Stimulating Agent Market Company Profiles Chapter 11: Erythropoietin Stimulating Agent Market Company Profiles - 108 Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 01 ERYTHROPOIETIN STIMULATING AGENT MARKET OVERVIEW Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
1.1 DEFINITIONS AND SCOPE (1/2) Definition • Erythropoietin is a hormone produced by the human kidney that speeds up the creation of red blood cells in response to decreasing oxygen levels in the tissues. It also aids in the process of erythropoiesis, which is the production of red blood cells. EPO is used to treat patients receiving chemotherapy or HIV-related medications. Globally, an increase in the number of people with HIV, cancer, and renal disorders is driving up demand for erythropoietin medicines (EPO). • Erythropoietin stimulating agent have a wide range of uses in various industries owing to their excellent strength-to-weight ratio, high stiffness, and durability. Some of the common uses of erythropoietin stimulating agent include Breast Cancer, Lung Cancer, Liver Cancer, Kidney Disorders, neural diseases and others. • The market for erythropoietin-stimulating agent is primarily driven by the rising prevalence of anemia. Anemia is a disorder marked by a lack of red blood cells or hemoglobin in the blood, which manifests as symptoms including exhaustion, breathlessness, and lightheadedness. The increasing need for ESAs in cancer is a significant growth factor for this market. ESAs are often used to treat cancer patients who have developed chemotherapy-induced anemia or renal failure-associated anemia. • There is a developing need for erythropoietin stimulating medications owing to the rising incidence of this disorder and other renal diseases that directly affect blood cells. Additionally, another reason contributing to the body's increasing demand for blood cells is the rising incidence of various diseases, including blood cancers. Over the course of the projected period, these variables are anticipated to fuel market expansion. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
RESEARCH METHODOLOGY Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
RESEARCH METHODOLOGY (1/9) Research Methodology Flowchart Market Scope & Definition Preliminary Research Data Gathering Data Triangulation Data Synthesis Data Analysis Data Validation Verification Quality Assurance Preliminary Research In the initial stage of research, the scope of Erythropoietin Stimulating Agent Market is defined. In this preliminary stage, the key data points in the market are identified which can be used to estimate the market to the best extent. The scope of Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC this report primarily focuses on the revenue generated from the services provided by the major players. To better gauge the market, the secondary focus is on different layers of Erythropoietin Stimulating Agent Market, such as services catering to disparate segments like applications. Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
RESEARCH METHODOLOGY (2/9) For this market, the volume of Erythropoietin Stimulating Agent Market as well as the varying price points were identified as key informational conjectures for market estimation in 2022. Market performance and trending market dynamics are some of the key questions that are studied during this stage. It also involves studying market factors and changing trends that are expected to affect the market in the future. Data Gathering Based on the scope of the market and the key data points, several secondary sources have been utilized for data gathering. The data gathering stage comprises a team of analysts who gather data by researching secondary research resources, accessing proprietary databases, and with primary research reaching out to key industry participants and opinion leaders (Sales & Marketing Directors, Services, Managers, Market Intelligence Directors as well as Technical Experts and Administrators) throughout the Erythropoietin Stimulating Agent ecosystem including end-use environments forming a crucial aspect of the value chain. The key sources for estimations remained the investments made by end-user verticals along with the sales figures of services suppliers in the market. Also, various trade bodies and associations were taken into consideration to understand the dynamics of each industry vertical and their respective investment scenarios. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
RESEARCH METHODOLOGY (3/9) Data Synthesis Stakeholders In this stage, a team of analysts incorporates the data that has been gathered by corroborating with various sources. These sources include industry participants, In- Research & Development house models, regulatory bodies key opinion leaders in the market ecosystem, and databases. In this stage, Erythropoietin Stimulating Agent producers patterns in historical data are identified and compared with the current scenario. Based on the Macro and Micro Regulatory Bodies/Testing Authorities factors prevalent in various geographies, various data models are used to assess the key countries for the Distributors market. The analysis also includes the identification of new companies that have entered the market scenario End User Segments and their impact on the market dynamics in the future. The data regarding end users is gathered from various Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC secondary sources (given towards the end of the presentation). Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
RESEARCH METHODOLOGY (4/9) Data Analysis After the corroboration of data, the team of analysts moves toward understanding how the market has evolved over the years. The overall market size is gathered after analyzing various segments and verticals of the market. An impact analysis is also carried out to see which factors will affect the market in the next few years. These factors have been researched concerning prominent economies across different geographic regions to understand their corresponding impact on the market. Verification Data verification is carried out at all stages of research. This stage, however, is dedicated to a more thorough check of all data points, which have been incorporated and rechecked against various data sources. Various C-Level executives and key opinion leaders are contacted for verification of the data. The total market for Erythropoietin Stimulating Agent Market is verified through the capital expenditure of various industry verticals. The market is also estimated for various key players in each of the service categories, offering another way of cross-validating the data. The data is then summarized and the key findings are disseminated. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
RESEARCH METHODOLOGY (5/9) Forecast Methodology Further, time series forecasting methodology is applied based on the various factors such as the service replacement, propensity to buy a service, suppliers and distribution margins along with the trade dynamics of the leading countries across the region. Average weighted ASPs are also considered while estimating the market value in the report. The estimates are further revalidated with the suppliers and Services operating in the market. However, some macroeconomic factors like inflation are not considered. Forecasting model is an iterative tool and is backed with historical trends of the market along with a regressive mathematical model which assesses the value based on factors such as capital expenditure, services, R&D investments and so on. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
RESEARCH METHODOLOGY (6/9) Assumptions & Research Methodology for Erythropoietin Stimulating Agent Market Erythropoietin Stimulating Agent Market Description • Nominal values (i.e. values are not adjusted w.r.t inflation) are considered in the market estimation • The base year is 2022. The forecast period is between 2023 and 2030. Historic and Forecast Value Average weighted selling prices of the Erythropoietin Stimulating Agent Market with respect to their diversified application are considered while arriving on the market in terms of volume. Pricing Average year USD exchange is considered for the estimation of historic values and average five years exchange rate is considered for forecast values. Exchange Rate Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
RESEARCH METHODOLOGY (7/9) Assumptions & Research Methodology for Erythropoietin Stimulating Agent Market S.NO SECONDARY SOURCES American Society of Hematology 1 Centers for Disease Control and Prevention 2 The New England Journal of Medicine 3 American Cancer Society 4 New York Heart Association (NYHA) 5 World Health Organization 6 The UK Kidney Association 7 European Hematology Association 8 Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC European Association of Hospital Pharmacists 9 American Society of Nephrology (ASN) 10 Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
RESEARCH METHODOLOGY (8/9) Primary Sources: Erythropoietin Stimulating Agent Market S.No Designation Company/Organizations Amgen Inc. 1 Business Development Manager F. Hoffmann La Roche Ltd. 2 Sales Manager Thermo Fisher Scientific Inc. 3 International Sales Director Johnson and Johnson 4 Service Marketing Executive Pfizer Inc. 5 Sales Manager Teva Pharmaceutical Industries Ltd. 6 Country Head 7 Kissei Group Director 8 Sanwa Kagaku Kenkyusho R&D and Business Development Manager Copyright ©2024 IndustryARC Biocon Copyright ©2024 IndustryARC 9 Sales Manager 3SBio Group 10 Marketing Executive Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
RESEARCH METHODOLOGY (9/9) HeXa-Grid Paradigm: 6. Data Presentation Data Analysis, Summarization, Key Finding & Reporting is done for efficient dissemination of information 5. Data Triangulation & Validation After data compilation, it is validated with various key opinion leaders and C-level Executives globally 4. Data Interpretation & Assessment Based on the macro and micro factors prevalent in various geographies, proprietary data models are used to assess the key countries for the market 1. Scope Definition: Defining scope of the Report: Analyzing its product type, disease cured, application, and Geographic penetration Market Assessment Competitive Landscape 2. Secondary Research: Based on the scope and segmentation, secondary research is done using public, private and subscribed sources 3. Primary Research: Reach out to all the stake holders involved in ecosystem: Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Industry Experts insights taken to gauge and validate key data points Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 02 ERYTHROPOIETIN STIMULATING AGENT MARKET EXECUTIVE SUMMARY Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
2. EXECUTIVE SUMMARY (1/3) Erythropoietin Stimulating Agent Market, 2022-2030 ($M) 8000.0 7000.0 6000.0 Revenue($M) 5000.0 4000.0 3000.0 2000.0 1000.0 0.0 2022 2023 2024 2025 2026 2027 2028 2029 2030 ❖ The global Erythropoietin Stimulating Agent market is estimated to reach $7,603.4 million by 2030 from $5,859.7 million in 2022 with a CAGR of 3.5% during the forecast period (2023-2030). ❖ Rising anemic patients and growing Incidences of Chronic Kidney Disease and Cancer are critical drivers for the market. ❖ Erythropoietin Stimulating Agents are commonly used to treat anemia in patients with chronic kidney disease or cancer, as well as in patients undergoing certain types of chemotherapy. ❖ These are also used in patients with anemia owing to other underlying medical conditions. Examples of Erythropoietin Stimulating Agents include epoetin alfa, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta. The major players in the Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Erythropoietin Stimulating Agent Market are investing heavily in research and development to improve the properties and applications of these materials. Source: IndustryARC Analysis, Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
2. EXECUTIVE SUMMARY (2/3) Erythropoietin Stimulating Agent Market Revenue Share, By Product Type, 2022 (%) Erythropoietin Stimulating Agent Market Revenue Share, By Disease Cured, 2022 (%) Epoetin-alfa Oncology Diseases Epoetin-beta Kidney Disorders Epoetin-Zeta Neural Disease Darbepoetin-alfa Wound healing Others Others ❖ Epoetin alfa dominated the Erythropoietin Stimulating ❖ Kidney Disorders dominated the Erythropoietin Agent Market with a value share of approximately 43.3% in Stimulating Agent Market with a value share of 49.4% in 2022. Epoetin alfa is a synthetic form of erythropoietin, a 2022. The world population is aging and anemia is more hormone that is naturally produced by the kidneys to common in older adults owing to factors such as stimulate the production of red blood cells in the bone malnutrition, chronic disease, and decreased kidney marrow. Epoetin alfa is used to treat anemia (low red blood function. As a result, the demand for Erythropoietin Copyright ©2024 IndustryARC Stimulating Agents is likely to increase in the future. Copyright ©2024 IndustryARC cell count) in people with certain medical conditions, such as chronic kidney disease, cancer, and HIV/AIDS. Source: IndustryARC Analysis, Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 04 ERYTHROPOIETIN STIMULATING AGENT MARKET FORCES Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
4.1. DRIVERS - IMPACT ANALYSIS (1/4) Erythropoietin Stimulating Agent Market- Drivers Short Term Medium Term Long Term Drivers (2022-2024) (2025-2027) (2028-2030) Growing incidences of chronic kidney disease and cancer to expand the market. Rising applications in cancer is driving the erythropoietin stimulating agent market. Cancerization of erythropoietin biosimilars is driving the erythropoietin stimulating agent market. Low High Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Source: IndustryARC Analysis & Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
4.1. DRIVERS - IMPACT ANALYSIS (2/4) Increasing disease burden of Anemia is opportunities for the Erythropoietin Stimulating Agent Market. ❖ Erythropoietin Stimulating Agent (ESA) market growth is primarily being driven by the rising occurrences of cancer and chronic renal disease. ESAs are a group of medicines that encourage the body to produce red blood cells. They are frequently prescribed to treat anemia brought on by chemotherapy for cancer, chronic renal disease, and other illnesses, as well as anemia that is a side effect of these treatments. ❖ According to the Centres for Disease Control and Prevention, chronic kidney disease affects older adults of age 65 and above at a rate of 38% prevalence, compared to those between the ages of 18 and 44 (7%) and 45 and 64 (13%) in the U.S. A greater need for erythropoietin stimulating medications is brought on by the rising incidence of this condition and other renal disorders that have a direct impact on blood cells. There is also a large demand for blood cells in the body as a result of the rising occurrences of various diseases, particularly blood cancers. Over the projected period, these variables are anticipated to contribute to market growth. ❖ The market for ESA is increasing beyond its traditional usage to encompass new indications such anemia associated with myelodysplastic syndromes, HIV infection, and other illnesses, as the prevalence of chronic kidney disease and cancer continues to rise. ❖ Red blood cell production is increased by ESA drugs, which can assist to reduce anemia's symptoms. The demand for ESA medications is anticipated to rise as anemia incidence rises as a result of ageing populations, rising chronic disease prevalence, and other factors. ❖ Additionally, the creation of new ESA medications that are more efficient, have fewer side effects, and require less frequent Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC administration may further spur market expansion. As an illustration, several producers are creating once-monthly long-acting ESA medications, which could offer patients significant benefits and lessen the strain on medical staff. Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 05 ERYTHROPOIETIN STIMULATING AGENT MARKET STRATEGIC ANALYSIS Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
5.1. VALUE CHAIN ANALYSIS (1/2) Erythropoietin Stimulating Agent Market Value Chain Analysis Erythropoietin Stimulating Agent Manufacturers Raw Material Suppliers Prescription and Administration Distribution Channels Payer Supplier/Distributor Reimbursement End Users Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Source: IndustryARC Analysis, Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
5.1. VALUE CHAIN ANALYSIS (2/2) ❖ The active pharmaceutical ingredients (APIs) necessary for the production of ESA are provided by raw material suppliers at the beginning of the value chain. ❖ These companies are in charge of producing ESA utilizing the APIs that the raw material suppliers provide. In order to provide high-quality ESA that adhere to regulatory requirements, they engage in substantial research and development operations. ❖ Once the ESA are manufactured, suppliers and distributors deliver them to a variety of locations, including hospitals, clinics, and pharmacies. Managing the logistics and delivery of the medications is the focus of the current stage. ❖ ESA drugs are prescribed and given to patients with anemia driven on by chronic renal disease, cancer chemotherapy, or other illnesses by healthcare professionals such nephrologists, oncologists, and hematologists. Patients with a chronic kidney illness, are undergoing chemotherapy for cancer, or are experiencing various forms of anemia ultimately take the medications. ❖ Payers including insurance companies and governmental organisations are essential links in the value chain. The price of ESA medications, which can be high, is reimbursed to healthcare providers. Additionally, payers bargain drug manufacturer pricing and encourage the usage of affordable substitutes. ❖ The final consumers of ESA medications are patients. They depend on medical professionals to identify and treat their diseases, and on payers to pay for the medications. Additionally, patients offer opinions on the effectiveness and adverse effects of ESA medications, which can guide future research and development initiatives. Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 08 ERYTHROPOIETIN STIMULATING AGENT MARKET - BY APPLICATION Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
8.1. HOSPITALS (1/3) ❖ Anemia is a common condition among patients with chronic kidney Hospitals: Erythropoietin Stimulating Agent Market Revenue, 2022-2030 ($M) disease, cancer, and other chronic illnesses. As the prevalence of these diseases increases, the demand for Erythropoietin Stimulating Agent drugs is expected to rise. ❖ As the global population ages, the prevalence of chronic diseases and 5000.0 anemia is expected to rise. This will lead to an increase in demand for 4000.0 Erythropoietin Stimulating Agent drugs in hospitals. According to the American Hospital Association in 2022, total number of all U.S. hospitals are 6,093 and number of rural community hospitals are 3000.0 Revenue($M) 1,796, number of urban community hospitals are 3,343 and number of community hospitals in a system are 3,483. ❖ Advances in technology have led to the development of new and 2000.0 more effective Erythropoietin Stimulating Agent drugs. These advancements have improved the efficiency of Erythropoietin 1000.0 Stimulating Agent therapy, which increases the adoption of these drugs in hospitals. ❖ Hospitals segment of Erythropoietin Stimulating Agent Market 0.0 Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC 2022 2023 2024 2025 2026 2027 2028 2029 2030 generated a revenue of $3680.0 m in 2022 and is projected to reach a revenue of $4933.9 m by 2030 growing at a CAGR of 3.9% during 2023-2030. Source: IndustryARC Analysis, Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
8.2. CLINICS (2/3) Clinics: Erythropoietin Stimulating Agent Market Revenue, 2022-2030 ($M) ❖ Erythropoietin Stimulating Agents are also used to treat anemia associated with cancer chemotherapy and in certain surgical procedures. As the use of ESAs in these indications expands, the market for Erythropoietin Stimulating Agents in the clinic is likely to 2000.0 grow. 1800.0 ❖ According to the U.S. Census Bureau and the National Center for 1600.0 Health Statistics (NCHS), between 2018 and 2020, there were 1400.0 about 2,000 retail health clinics (RHCs) in the US that offered easy access to healthcare inside of pharmacies, supermarkets, and 1200.0 Revenue($M) supercenter retailers, but the majority were in urban areas. 1000.0 ❖ The adoption of biosimilars in the Erythropoietin Stimulating 800.0 Agents market could increase competition, potentially leading to 600.0 lower costs and greater accessibility of Erythropoietin Stimulating 400.0 Agents in the clinics. ❖ Clinics segment of Erythropoietin Stimulating Agent Market 200.0 generated a revenue of $1603.4 m in 2022 and is projected to Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC 0.0 2022 2023 2024 2025 2026 2027 2028 2029 2030 reach a revenue of $1997.9 m by 2030 growing at a CAGR of 3.0% during 2023-2030. Source: IndustryARC Analysis, Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 09 ERYTHROPOIETIN STIMULATING AGENT MARKET - BY GEOGRAPHY Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
9.4. APAC Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
9.4.1 CHINA ❖ In 2021, the Erythropoietin Stimulating Agent (ESA) market in China was growing China: Erythropoietin Stimulating Agent Market Revenue, 2022 - 2030 ($M) steadily. China is one of the largest markets for ESAs in the world, and the demand for these drugs is increasing due to the rising prevalence of chronic 700 kidney disease and cancer in the country. 600 ❖ Several multinational pharmaceutical companies, including Amgen, Roche, and Johnson & Johnson, have a strong presence in the ESA market in China. Local 500 Chinese companies such as 3SBio and Bio-Thera Solutions also manufacture and sell ESAs in the country. In 2018, the Chinese government implemented a 400 centralized procurement program for certain drugs, including ESAs, in an effort 300 to reduce healthcare costs. ❖ In 2017, the Chinese Food and Drug Administration issued warnings about the 200 use of ESAs in cancer patients, citing potential risks such as blood clots and 100 increased mortality. Overall, the ESA market in China is expected to continue growing, but companies will need to navigate regulatory challenges and 0 increased competition to succeed in the market. 2022 2023 2024 2025 2026 2027 2028 2029 2030 Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC ❖ China ESA Market generated a revenue of $347.6 million in 2022 and is projected to reach a revenue of $641.8 million by 2030 growing at a CAGR of 8.0% during 2023-2030. Source: IndustryARC Analysis, Expert Insights Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
CHAPTER - 11 ERYTHROPOIETIN STIMULATING AGENT MARKET COMPANY PROFILES Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
11.1. AMGEN INC. (1/3) Amgen Inc :Product Portfolio Product Description EPOGEN®is a prescription medicine for people on dialysis with anemia due to CKD that acts like a hormone called erythropoietin. This hormone plays an important role in making red blood cells. EPOGEN®is used to treat anemia by helping the body create more red blood cells. EPOGEN®decreases the need for red blood cell transfusions. Blood transfusions are given for chronic anemia, but transfusions may also have risks, such as different types of reactions and infections. EPOGEN®increases Hb levels and decreases the need for blood transfusions. Address: One Amgen Center Drive, Thousand Oaks, CA Tel: +1 805-447-1000 Website: www.amgen.com Epogen Business Segments Amgen Inc. Description Establishing Year 1980 Aranesp®is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on dialysis and not on dialysis. Thousand Oaks, California, U.S. Aranesp Headquarters No. of Employees (2021) 25,200 employees Revenue (2022) $26,323 million Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Global Outreach 100 countries Source: Company Website Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
11.1. AMGEN INC. (2/3) Financials: Amgen inc Revenue, 2020-2022 ($M) Amgen Inc,Revenue By Geography, 2022 (%) 26323 6% 26400 26200 25979 26000 27% Revenue ($M) 25800 U.S. 25600 25424 ROW 25400 Other 25200 67% 25000 24800 2020 2021 2022 Amgen Inc,Revenue By Products, 2022 (%) ENBREL Prolia 3% 4% 6% 21% Otezla XGEVA 6% Aranesp Nplate 6% Repatha KYPROUS 7% Copyright ©2024 IndustryARC Neulasta EVENITY Copyright ©2024 IndustryARC 18% 7% Other 10% 12% Source: Company Website, Annual Reports Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
11.1. AMGEN INC. (3/3) Developments: Date Development Description Amgen announced the successful completion of its acquisition of worldwide rights to Otezla®(apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (NASDAQ:CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company, which was completed on Nov. 20. November 21, 2019 Acquisition Amgen announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. October 20, 2022 Acquisition Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Source: Company Website Inquiry Before Buying +1 518 282 4727 | | | Buy Now sales@industryarc.com
Thank You! IndustryARC +1 614-588-8537/38 sales@IndustryARC.com Copyright ©2024 IndustryARC Copyright ©2024 IndustryARC Page - 35 | Web - www.industryarc.com Mail – sales@industryarc.com
